Stock Analysis
Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis
Agios Pharmaceuticals, Inc. (AGIO) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Agios Pharmaceuticals, Inc. (AGIO) currently has an AIQ Score of 56/100, indicating a neutral setup. Momentum is the strongest factor at 61/100. Risk is the weakest current factor at 47/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
AGIO at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $31.59 |
| AIQ Score | 56/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $1.89B |
| P/E Ratio (TTM) | -5 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$1.09 |
| Revenue (Q3 FY2026) | $55.39M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.93 |
| Volume | 371.34K |
| 52-week range | $22.24-$46.00 |
| RSI 14 | 46.26 |
| 50-Day SMA | $33.09 |
| 200-Day SMA | $31.85 |
| Analyst Price Target | $35.00 |
| Next Earnings | Feb 11, 2027 |
AGIOAgios Pharmaceuticals, Inc.
Healthcare / Biotechnology
Low Priority
In Line With Peers
Latest quote
- Momentum61
- Value52
- Quality58
- Risk resilience47
- Sentiment—
AGIO Stock Analysis Summary
Agios Pharmaceuticals, Inc. (AGIO) currently has an AIQ Score of 56/100, indicating a neutral setup. Momentum is the strongest factor at 61/100. Risk resilience is the weakest current factor at 47/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, AGIO has AIQ Score of 56/100 with Momentum base of 61/100 and fading Risk resilience at 47/100. Wait for component alignment before adding exposure.
Healthcare · -0.54% stock move · AGIO classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is AGIO Bullish or Bearish Right Now?
AGIO currently has a neutral overall setup. Momentum is the strongest factor at 61/100, while Risk Resilience is weakest at 47/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Analyst target implies +10.79% upside from the latest quote.
- - Risk Resilience is weak at 47/100.
- - Price is -0.80% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (35 vs 3).
Current Consensus
AGIO's Technical Analysis Consensus is currently Strong Sell, with 3 buy, 8 neutral, and 35 sell votes. AGIO's 14-day RSI is 46.26, which places the stock in a neutral momentum range. AGIO's beta is 0.93, indicating market sensitivity broadly in line with the market.
What Changed in AGIO?
The largest recent change in AGIO is Momentum moving down by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the AGIO Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
AGIO Decision Framework
Public evidence layers, setup checks, and risk context for Agios Pharmaceuticals, Inc..
Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis
Agios Pharmaceuticals, Inc. has an AIQ Score of 56/100 in a Neutral regime. Momentum is strongest at 61/100. Beta is 0.93, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | AGIO is in a Neutral AIQ regime with score 56/100. |
| Signal Conflict | The primary conflict is that momentum leads at 61/100 while risk lags at 47/100. |
| Factor Evidence | Momentum 61/100 · Value 52/100 · Quality 58/100 · Risk 47/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 61/100.
Momentum is 61/100 and RSI (14) is 46.3.
AGIO is in a Neutral regime at 56/100.
Risk factor is 47/100 with beta 0.93 and annual volatility 79.96%.
Current conflict: momentum leads at 61/100 while risk lags at 47/100.
AGIO Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
AGIO Fundamentals
AGIO valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
AGIO Technical Analysis
AGIO technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
AGIO Stock Catalysts
Track AGIO earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
AGIO Dividend Analysis
AGIO dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
AGIO Financial Data
AGIO revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
AGIO Risk Analysis
AGIO volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
AGIO Stock News
AGIO stock news, market tone, recent headlines, and catalyst context.
AGIO vs Biotechnology Peers
Current peer cohort: AGIO · ALMS · AMLX · ANAB · ARGX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| AGIO Current stock | 56/100 | 52/100 | 61/100 | 47/100 | 0.07 | 79.96% | Current |
| ALMS Alumis Inc. | 20/100 | — | 13/100 | 20/100 | 0.65 | 137.60% | AGIO vs ALMS |
| AMLX Amylyx Pharmaceuticals, Inc. | 78/100 | — | 90/100 | 48/100 | 1.35 | 87.03% | AGIO vs AMLX |
| ANAB AnaptysBio, Inc. | 56/100 | 74/100 | 36/100 | 46/100 | 0.78 | 64.84% | AGIO vs ANAB |
| ARGX argenx SE | 74/100 | 70/100 | 74/100 | 70/100 | 0.28 | 37.87% | AGIO vs ARGX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for AGIO: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching AGIO
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for AGIO
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
AGIO Stock FAQ
What is AGIO stock price today?
Agios Pharmaceuticals, Inc.'s current stock price is $31.59. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is AGIO bullish or bearish right now?
AGIO's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is AGIO's market cap?
AGIO's market cap is $1.89B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is AGIO's current P/E ratio?
AGIO's current P/E ratio is -5 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is AGIO's RSI?
AGIO's 14-day RSI is 46.26 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is AGIO above its 50-day and 200-day moving averages?
AGIO is -4.53% from its 50-day SMA and -0.80% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is AGIO's next earnings date?
AGIO's next earnings date is currently listed as Feb 11, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does AGIO pay a dividend?
AGIO's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.